What You Should Know:
- Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces today the launch of its first therapy selection test, the My Phenome Hungry Gut test.
- This is a first-of-its-kind obesity test and will determine if a patient’s phenotype is Hungry Gut (Satiety) or feeling hungry shortly after eating a meal. If a patient is Hungry Gut phenotyped, providers are able to more precisely and
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
What You Should Know:
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health
Read More
Accenture: Data Collaboratives Hold Great Promise for Accelerated Healthcare Progress and Precision Medicine
What You Should Know:
- Accenture published Fast-Forwarding Healthcare through Data Collaboratives Report to discover how best health ecosystem players access data to fast-forward healthcare.
- Data generated by technical and scientific advances, like connected health devices, consumer health and medical-grade digital apps, individual multi-omics profiling data and the move to cloud storage, holds great promise for accelerated healthcare progress and precision medicine, and data
Read More
PathGroup Expands Operations with Proscia Concentriq Dx
What You Should Know:
- PathGroup, one of the largest providers of anatomic, clinical, digital, and molecular pathology services in the United States, is expanding its operations with Proscia's software platform (Concentriq® Dx) to further enhance the delivery of faster, higher quality results for millions of patients, helping to better inform treatment decisions.
- PathGroup currently supports more than 15,000 referring physicians and over 200 hospital
Read More
Tempus, Pfizer Partner to Advance Oncology Therapeutic Development
What You Should Know:
- Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology.
- Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology.
-
Read More
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know:
- Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.
- This multi-omics approach is being used by Actuate Therapeutics in support
Read More
Unintended Bias in AI-Driven Healthcare Applications
What You Should Know:
- Over the past few years, Artificial Intelligence (AI), and more specifically, Machine Learning (ML) technology, have experienced rapid adoption in the healthcare space as tools for diagnosis and decision-making. Such tools are intended to address challenges in the healthcare system to both processes and put into practice the proliferating medical findings, and also to support delivery of the promise of personalized and precision medicine.
- Unintended bias in AI and
Read More
5 Things Every Smart Operating Room Should Prioritize – Surgery
The healthcare industry is in the middle of deep digital transformation across every aspect of the patient journey. Technology has always been important in healthcare, but COVID-19 has accelerated advancements, improving the way care is delivered. The pandemic also increased patient interest in being more involved in their healthcare decisions. And when patients are more involved, they are typically more satisfied with their experience and have better health outcomes. From remote patient
Read More
Boosting Clinical Trial Recruitment Requires Humanity – and Technology
Clinical trials should be a time of promise for better patient outcomes, as they explore new ways to potentially help patients suffering from a variety of conditions. Instead, this phase of treatment development is often met with exasperation as patients, researchers, and drug developers deal with the many barriers to clinical trial recruitment and access.
There are two central – and intrinsically linked – problems with the current state of clinical trial recruitment in the U.S.:
Read More
7 Life Sciences Executive Predictions to Watch in 2023
Tracy Curley, CFO and interim CEO at iSpecimen
Focusing on the macroeconomic environment, which remains impacted by the lingering COVID-19 pandemic, there continues to be uncertainty about the strength of the global, Asia Pacific, UK and US economies. High-interest rates and a potential recession remain a concern for all market participants. At ISPC, we are closely monitoring the pace of specimen transactions. We believe that this industry can be resilient through a continued economic
Read More
